Drug Profile
Daridorexant - Idorsia Pharmaceuticals
Alternative Names: ACT-541468; DORA; Nemorexant - Idorsia PharmaceuticalsLatest Information Update: 12 Nov 2019
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Developer Idorsia Pharmaceuticals
- Class Sleep disorder therapies
- Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Insomnia
- Phase I Sleep apnoea syndrome
Most Recent Events
- 22 Oct 2019 Efficacy and adverse events data from pooled analysis of two phase II trials in Insomnia released by Idorsia Pharmaceuticals
- 10 Oct 2019 Idorsia Pharmaceuticals completes a phase I trial in Healthy volunteers (In adults, In the elderly) in Netherlands (PO, Tablet) (NCT03892902)
- 24 Sep 2019 Idorsia Pharmaceuticals initiates a phase I trial in Healthy volunteers (In adults, In the elderly) and in Hepatically-impaired patients in Germany (PO) (NCT04024332) (EudraCT2019-002159-40)